JASON VAN PELT

Workforce, PPE, and industrial safety issues

EPA/environmental regulations. Issues related to PFAS.

Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.

Trade issues related to Mexico.

Issues related to privacy.

Advise client on general financial services issues including: tax reform; Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L.111-203) implementation and regulatory reform.

Issues related to defense policy and procurement; FY2027 National Defense Authorization Act (H.R.8800/S.4784); FY2027 Department of Defense Appropriations Act (H.R.9495).

Issues related to tax reform; international taxation.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Issues related to health diagnostics and employment.

DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations Act (H.R.9495).

Supporting extension of Enhanced Advanced Premium Tax Credits.

Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.

Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); GENEROUS Medicaid Drug Pricing Model.

Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.

Education about the importance of OTC products and benefits under Medicare Advantage.

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.

Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.

Issues and funding related to community mental health and substance use disorder.

Issues related to price transparency and site-neutral payment reforms to reduce out-of-pocket costs for patients with blood cancer.

Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.

Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).

Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.

General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.

Policies impacting the supply chain and manufacturing of medical devices and technology including tariffs.

Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Issues related to tax reform; international taxation.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Proposed Rule: Regulation for Federal Financial Assistance (Docket No. OMB-2026-0034; RIN 0348-AB88).

General education about the importance of support for federal funding of scientific research.

General educationand support for federal funding of medical research.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals; Section 301 tariffs.

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R.8646); S.2658, Medication Affordability and Patent Integrity Act; S.3014, Ensuring Timely Access to Generics Act of 2025.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.

Education about the impact of J-1 visa interview pause and travel ban impact for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.

Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).

Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing; H.R.6130, Alzheimers Screening and Prevention (ASAP) Act of 2025.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to tax-exempt status of philanthropies.

Issues related to defense acquisition and procurement policy within the FY2027 National Defense Authorization Act (H.R.8800/S.4784) and other legislation.

Legislative, regulatory, and funding issues impacting the nuclear energy industry; FY2027 Energy and Water Development and Related Agencies Appropriations Act (H.R.9022).

Legislative issues related to mental health/severe mental illness; advocacy for Medicaid funding and housing; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).

Issues related to tax-exempt status of philanthropies.

Issues related to Medicaid rate-setting for pediatric care.

Discussions regarding U.S. export promotion and efforts to increase trade and investment flows between countries in North America, Asia, and Europe (no specific legislation). Discussions regarding international economic policy issues related to trade promotion (no specific legislation). Discussions regarding efforts to strengthen economic and commercial ties between the United States and allied countries like South Korea, Taiwan, Japan, the UK, and the European Union (no specific legislation).

Issues related to price transparency and site-neutral payment reforms to reduce out-of-pocket costs for patients with blood cancer.

Workforce, PPE, and industrial safety issues

Trade issues related to Mexico.

Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.

Advise client on general financial services issues including: tax reform; Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L.111-203) implementation and regulatory reform.

Issues related to privacy.

Issues related to defense policy and procurement; FY2027 National Defense Authorization Act (H.R.8800/S.4784); FY2027 Department of Defense Appropriations Act (H.R.9495).

General education to advance policies that support innovation in the medical device industry. Issues related to coverage and reimbursement of diagnostic tests, including issues related to FDA regulation of medical devices. Issues related to medical device sterilization. Policy issues related to the regulation of artificial intelligence for medical technology. Issues related to cybersecurity of medical devices manufactured in China. Policies that could impact supply chain for medical technology. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.

Policies impacting third party repair of medtech. Issues related to competitive bidding in the FY2027 National Defense Authorization Act (H.R.8800/S.4784).

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); issues related to COPD and Type One Diabetes (T1D).

Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Reimbursement issues related to proton therapy.

Issues related to health diagnostics and employment.

DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations Act (H.R.9495).

Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.

Supporting extension of Enhanced Advanced Premium Tax Credits.

Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Section 301 tariffs.

Issues related to CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models).

Education about the importance of OTC products and benefits under Medicare Advantage.

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Policies impacting access to over-the-counter products; FY2027 Financial Services and General Government Appropriations Act (H.R.8495).

Legislative issues related to mental health/severe mental illness; advocacy for Medicaid funding and housing; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260).

Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations Act (H.R.9495); FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Support coverage of and access to all epilepsy treatments. Support PBM reform.

Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.

Issues and funding related to community mental health and substance use disorder.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals; Section 301 tariffs.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.

Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260); FY2027 National Defense Authorization Act (H.R.8800/S.4784).

Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

General educationand support for federal funding of medical research.

Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.9260). Proposed Rule: Regulation for Federal Financial Assistance (Docket No. OMB-2026-0034; RIN 0348-AB88).

General education about the importance of support for federal funding of scientific research.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act, H.R.8800/S.4784), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Education about how to improve the quality of kidney care treatment, expand innovation, and other insurance/payment policies. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).

Education about how to improve the quality of kidney care treatment and expand innovation. Modernize Medicares payment system for end-stage renal disease (ESRD). Medicare coverage and reimbursement related to dialysis. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750). Improving Home Dialysis Act of 2026 (H.R.8875).

General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments. Education and awareness regarding genetic medicines for rare and ultra-rare diseases.

Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act (H.R.8800/S.4784) and FY2027 Department of Defense Appropriations Act (H.R.9495). Education and discussion regarding Broad Institute capabilities and technologies relevant to national biological intelligence, biosurveillance, and reconnaissance (ISR).

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.

Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing.

Issues related to defense acquisition and procurement policy within the FY2027 National Defense Authorization Act (H.R.8800/S.4784) and other legislation.

Legislative, regulatory, and funding issues impacting the nuclear energy industry; FY2027 Energy and Water Development and Related Agencies Appropriations Act (H.R.9022).

Advocacy for site-neutral payment reforms to reduce out-of-pocket costs for patients with blood cancer.

Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).

Education about how to improve the quality of kidney care treatment and expand innovation. Kidney Care Access Protection Act of 2025 (H.R.6214/S.2730). Restore Protections for Dialysis Patients Act (H.R.8594/S.4750).

Issues related to health diagnostics and employment.

Discussions regarding U.S. export promotion and efforts to increase trade and investment flows between countries in North America, Asia, and Europe (no specific legislation). Discussions regarding international economic policy issues related to trade promotion (no specific legislation). Discussions regarding efforts to strengthen economic and commercial ties between the United States and allied countries like South Korea, Taiwan, Japan, the UK, and the European Union (no specific legislation).

Reimbursement issues related to proton therapy.

General educationand support for federal funding of medical research.

General education about the importance of support for federal funding of scientific research.

Support for funding of research and policy issues related to indirect costs and accessibilityof grants and contracts. FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.

Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.

Issues related to drug pricing; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to CMMI Drug Pricing Demonstration Programs.

Support affordable access to health insurance including through extension of Enhanced Advanced Premium Tax Credits.

Funding for epilepsy program research at CDC, NIH, DoD; S.494/H.R.1189, National Plan for Epilepsy Act; FY2027 Department of Defense Appropriations; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Support coverage of and access to all epilepsy treatments. Support PBM reform.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Supporting extension of Enhanced Advanced Premium Tax Credits.

Supporting established funding levels for Medicare and Medicaid and protection of Medicaid's financing structure.

DoD funding-Congressionally Directed MS Research Program. NIH funding, FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. Ensuring access to care and coverage for people living with multiple sclerosis. Healthcare research, FY2027 Department of Defense Appropriations.

Issues and funding related to community mental health and substance use disorder.

General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments.

Federal funding for research and policy issues related to biomarkers and stress biology, including potential applications in defense and human performance.FY2027 National Defense Authorization Act and FY2027 Department of Defense Appropriations.

General education about biomedical research and support for scientific funding. Policies to advance AI supported long-term, population-scale health studies and accelerate translation of research findings to treatments.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties. Education about the impact of J-1 visa interview pause and travel ban for foreign physicians. Issues related to the proposed rule regarding establishing a fixed time period of admission and an extension of stay procedure for nonimmigrant academic students, exchange visitors, and representatives of foreign information media.

General education about the role of international medical graduates, specifically at U.S. teaching hospitals and in underserved communities and primary care specialties.

EPA/environmental regulations. Issues related to PFAS.

Issues related to tax reform; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation, international tax and third-party litigation funding provisions.

Workforce, PPE, and industrial safety issues

Issues related to defense acquisition and procurement policy within the FY2027 National Defense Authorization Act and other legislation.

Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885/S.3989, Community TEAMS Act of 2025; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 National Defense Authorization Act.

Education about the importance of OTC products and benefits under Medicare Advantage.

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine.

Legislative issues related to mental health/severe mental illness; advocacy for Medicaid funding and housing; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations.

Issues related to privacy.

Advise client on general financial services issues including: tax reform; Dodd-Frank Wall Street Reform and Consumer Protection Act (P.L.111-203) implementation and regulatory reform.

Issues related to defense policy and procurement; FY2026 Department of Defense Appropriations Act (H.R.4016/S.2572); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75); FY2027 National Defense Authorization Act; FY2027 Department of Defense Appropriations.

Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2027 National Defense Authorization Act); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations.

Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.

Policies impacting the supply chain and manufacturing of medical devices and technology including tariffs. Issues related to reimbursement in Japan.

Policies impacting third party repair of medtech. Issues related to competitive bidding in the NDAA.

General education to advance policies that support innovation in the medical device industry. Issues related to the coverage and reimbursement of medical devices and technology, including AI. H.R.5343, Ensuring Patient Access to Critical Breakthrough Products Act.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing.

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to tax reform; R&D tax credit; orphan drug tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to health diagnostics and employment.

Discussions regarding U.S. export promotion and efforts to increase trade and investment flows between countries in North America, Asia, and Europe (no specific legislation). Discussions regarding international economic policy issues related to trade promotion (no specific legislation). Discussions regarding efforts to strengthen economic and commercial ties between the United States and allied countries like South Korea, Taiwan, Japan, the UK, and the European Union (no specific legislation).

Discussions regarding U.S. export promotion and efforts to increase trade and investment flows between countries in North America, Asia, and Europe (no specific legislation). Discussions regarding international economic policy issues related to trade promotion (no specific legislation). Discussions regarding efforts to strengthen economic and commercial ties between the United States and allied countries like South Korea, Taiwan, Japan, the UK, and the European Union (no specific legislation).

Reimbursement issues related to proton therapy.

General education about biomedical research and support for scientific funding.

General education about biomedical research and support for scientific funding.

General education about biomedical research and support for scientific funding.

Issues related to market-based solutions to drug pricing, branded medication affordability, and patient access.

Policiesimpacting pharmaceutical development, patient access, drug pricing, and supply chain.

Medicare-funded Graduate Medical Education; Osteopathic Funding and Representation; H.R.2314/S.2715, FAIR Act; H.R.3885, Community TEAMS Act of 2025; FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60); FY2026 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.5304/S.2587); FY2026 Department of Defense Appropriations Act (H.R.4016/S.2572); H.R.1, One Big Beautiful Bill Act (P.L.119-21), higher education accountability provisions.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Issues related to tax reform; R&D tax credit; international taxation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, step therapy, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.